FibroGen, Inc. — Form 10-Q Summary
Company identification: The supplied filing is for FibroGen, Inc., not Kyntra Bio, Inc. It covers the quarter and nine months ended September 30, 2015; financial statements are unaudited.
Business context
FibroGen is a clinical-stage biopharmaceutical company. Its lead candidate, roxadustat, was in Phase 3 development for anemia in chronic kidney disease (CKD); FG-3019 was in Phase 2 studies for several fibrosis-related conditions and pancreatic cancer. Revenue to date came principally from Astellas and AstraZeneca collaborations, not product sales.
Financial performance and position
Amounts below are in millions of dollars except per-share data.
| Metric | Q3 2015 | Q3 2014 | Nine months 2015 | Nine months 2014 |
|---|---|---|---|---|
| Revenue | $19.5 | $13.7 | $156.4 | $121.5 |
| Operating expenses | $63.3 | $50.8 | $185.6 | $123.6 |
| Operating loss | $(43.8) | $(37.1) | $(29.2) | $(2.1) |
| Net loss | $(45.1) | $(39.5) | $(34.4) | $(8.9) |
| Net loss per share, basic and diluted | $(0.74) | $(2.93) | $(0.57) | $(0.67) |
| Operating cash flow | Not presented by quarter | Not presented by quarter | $20.7 | $46.2 |
- Q3 revenue rose 43%; nine-month revenue rose 29%. The nine-month increase primarily reflected a $120 million AstraZeneca upfront payment and a $15 million development milestone received in Q2 2015, as well as increased collaboration activity. Revenue recognition includes deferred amounts and is affected by collaboration accounting judgments.
- R&D expense increased 55% year over year for the nine-month period to $154.2 million, mainly due to progression of roxadustat Phase 3 trials and FG-3019 Phase 2 trials. G&A increased 30% to $31.4 million, including public-company costs. No gross margin is presented in the filing.
- Nine-month operating cash flow was positive despite the net loss, supported in part by a $28.5 million increase in deferred revenue and noncash expenses. It declined from $46.2 million in 2014. Cash and cash equivalents at September 30 were $208.7 million.
- Short- and long-term investments totaled approximately $140.8 million; accounts receivable was $7.4 million. Cash, cash equivalents, investments, and receivables totaled $356.9 million, excluding restricted cash. Current liabilities were $59.0 million.
- Long-term lease financing obligations were $97.0 million, and product development obligations were $15.4 million. The filing reports no material change in contractual obligations versus the 2014 Form 10-K.
- Accumulated deficit was $356.7 million. The company had no product-sale revenue and maintained a full valuation allowance against deferred tax assets.
Material changes and outlook
- Operating expenses grew faster than revenue, and nine-month net loss widened to $34.4 million from $8.9 million. The per-share comparison is affected by the post-IPO increase in weighted-average shares.
- Management said existing cash, investments, and expected collaboration payments should fund working capital and capital expenditures for at least 12 months, while cautioning that assumptions may change. It expected continuing losses and stated substantial additional funding may be needed.
- FibroGen reported roxadustat Phase 3 enrollment above 80% of cumulative target enrollment for its three studies. It anticipated a U.S. NDA submission in 2018 and initiating a China NDA submission in 2016. China Phase 3 trial-site initiation was underway, with enrollment expected by year-end 2015.
- Roxadustat development spending outside China was expected to shift further to AstraZeneca after FibroGen reached its $116.5 million funding cap; $104.7 million had been incurred by September 30, and management expected to reach the cap before December 2015. China development costs are shared equally with AstraZeneca.
- FG-3019 IPF trial enrollment was more difficult following approval of competing therapies; reaching the 90-patient first-line target in the first half of 2016 depended on recruiting at sites outside the U.S. In a small pancreatic cancer study, three of four patients in the FG-3019 plus standard-of-care arm were reported converted to operable cancer; these early results are not definitive.
Risks, contingencies, and unusual items
- The business is highly dependent on successful roxadustat trials, regulatory approvals, and continued Astellas and AstraZeneca collaboration and funding. Clinical results, safety findings, trial enrollment, manufacturing, and regulatory review could delay or prevent approval.
- Roxadustat Phase 3 studies include major cardiovascular safety endpoints. The filing also discusses possible interaction with statins and uncertainty about long-term safety and efficacy.
- FG-3019 has no collaboration partner and requires further clinical development; enrollment for IPF and supply/manufacturing capacity are risks. Competition and reimbursement uncertainty may affect future commercialization.
- China-specific risks include regulatory uncertainty, manufacturing licensing, reimbursement and tendering, currency and capital controls, intellectual-property protection, and limits on moving funds from Chinese subsidiaries.
- Deferred revenue was $98.7 million, including amounts tied to future services and China commercial product delivery. Collaboration revenue timing depends on estimates and judgments about deliverables and performance periods.
- The company reported no material legal proceedings, no material off-balance-sheet arrangements, and no material change in market-risk exposure. Disclosure controls were assessed as effective at a reasonable-assurance level.
Key facts for investors to verify
- Confirm the filing issuer is FibroGen, Inc.; the request metadata names a different company.
- Track roxadustat Phase 3 enrollment, safety endpoints, partner funding obligations, and progress toward the stated U.S. and China regulatory timelines.
- Assess cash use and liquidity alongside collaboration-payment timing, deferred revenue, and the company’s stated expectation of at least 12 months of funding.
- Monitor FG-3019 IPF enrollment, confirmatory clinical data, pancreatic cancer study progress, and manufacturing supply.
- Review the terms and remaining conditions of collaboration agreements, including potential milestone payments, cost-sharing caps, and termination rights.